Nice | Ticagrelor for the treatment of acute coronary syndrome ACS

4th November 2011 by Louise Hudman

Ticagrelor is a PO drug which inhibits platelet aggregation. In combination with aspirin it is more effective than clopidogrel + aspirin at reducing the endpoint of MI or death from vascular events.

It will be started by secondary care and continued by cardiologists, so we shouldn’t really have to initiate it.

It will be started in patients who’ve had a STEMI where primary percutaneous coronary intervention (PCI) is considered and also in patients with a NSTEMI who have certain other risk factors.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"We have used LocumDeck for a number of months now and find it really useful when booking locums. You can see the availability of GPs, their documents are all loaded on the site and you can book instantly – it takes minutes to do. There are also no expensive locum agency fees to pay – just the GP’s actual payment. It's quick and hassle-free."

Lesley Munro-Faure, Managing Partner at Unity Health, York

See the full list of features within our NASGP membership plans

Membership